Cross-Species Organ Transplantation Market Report 2025

The cross-species organ transplantation market size has grown strongly in recent years. It will grow from $13.98 billion in 2024 to $15.2 billion in 2025 at a compound annual growth rate (CAGR) of 8.7%. The growth during the historic period can be attributed to extensive animal model experimentation, the emergence of bioethical debates, the increasing prevalence of chronic diseases, experimental pig-to-primate transplants, and high mortality rates from end-stage organ failure.

The cross-species organ transplantation market size is expected to see strong growth in the next few years. It will grow to $20.95 billion in 2029 at a compound annual growth rate (CAGR) of 8.3%. The growth in the forecast period can be attributed to rising demand for transplantable organs, increasing investments in regenerative medicine, the global burden of chronic kidney and liver diseases, patient advocacy for transplant access, and the declining availability of human donors. Major trends during this period include the production of gene-edited pig organs, human-compatible genome engineering, integration of artificial intelligence in organ matching, 3D bioprinting of vascular structures, advancements in machine perfusion and organ preservation technologies, and nanoscale drug delivery systems for immunosuppression.

The rising incidence of organ failure, particularly trauma-related multiple organ failure, is expected to drive the growth of the cross-species organ transplantation market in the coming years. Cross-species organ transplantation, also known as xenotransplantation, involves transplanting organs from animals into humans to address critical shortages of donor organs. The growing adoption of genetic engineering plays a pivotal role in this market by enabling the modification of animal organs to reduce immune rejection, making them more compatible for human recipients. For example, by July 2023, the American Society of Gene & Cell Therapy reported an increase in gene therapies in Phase II clinical trials from 247 in the first quarter to 260 in the second quarter, highlighting the rapid expansion of genetic engineering applications. This trend supports the development of xenotransplantation solutions capable of addressing the shortage of human organs.

Companies in the cross-species organ transplantation market are increasingly forming strategic partnerships to accelerate clinical trials and regulatory approvals. Strategic partnerships allow organizations to leverage each other’s expertise and resources, fostering innovation without requiring full mergers. For instance, in February 2025, United Therapeutics, a US-based biotechnology company, partnered with eGenesis to begin FDA-approved clinical trials for genetically modified pig kidney transplants in humans. These trials aim to provide a sustainable alternative for patients with kidney failure, addressing the global donor organ shortage.

In December 2023, United Therapeutics Corporation further strengthened its xenotransplantation capabilities by acquiring Miromatrix Medical Inc., a US-based company specializing in bioengineered organs through decellularization and recellularization techniques. This acquisition enhances United Therapeutics’ ability to develop advanced cross-species organ transplantation solutions, combining genetic engineering and bioengineering approaches to expand the availability of transplantable organs.

Major players in the cross-species organ transplantation market are Pfizer Inc, F. Hoffmann-la Roche Ltd, Sanofi SA, Novartis AG, Optipharm Co Ltd, Astellas Pharma Inc., United Therapeutics Corporation, TransMedics Group Inc., Artivion Inc., eGenesis Inc., Organ Recovery Systems Inc., OrganOX Ltd, Paragonix Technologies Inc., Qihan Biotech, PorMedTec Co., XenoTheraputics Inc., Makana Therapeutics Inc., Preservation Solutions Inc., Nzeno Ltd, Infigen Inc.

North America was the largest region in the cross-species organ transplantation market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in cross-species organ transplantation market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa. The countries covered in the cross-species organ transplantation market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Note that the outlook for this market is being affected by rapid changes in trade relations and tariffs globally. The report will be updated prior to delivery to reflect the latest status, including revised forecasts and quantified impact analysis. The report’s Recommendations and Conclusions sections will be updated to give strategies for entities dealing with the fast-moving international environment.

The sudden escalation of U.S. tariffs and the consequent trade frictions in spring 2025 are severely impacting the healthcare sector, particularly in the supply of critical medical devices, diagnostic equipment, and pharmaceuticals. Hospitals and healthcare providers are facing higher costs for imported surgical instruments, imaging equipment, and consumables such as syringes and catheters, many of which have limited domestic alternatives. These increased costs are straining healthcare budgets, leading some providers to delay equipment upgrades or pass on expenses to patients. Additionally, tariffs on raw materials and components are disrupting the production of essential drugs and devices, causing supply chain bottlenecks. In response, the industry is diversifying sourcing strategies, boosting local manufacturing where possible, and advocating for tariff exemptions on life-saving medical products.

Cross-species organ transplantation, commonly referred to as xenotransplantation, involves transferring living cells, tissues, or whole organs from one species to another, most often from animals to humans. The primary aim of xenotransplantation is to alleviate the shortage of human donor organs for patients requiring transplants.

The main product types in cross-species organ transplantation include organ preservation solutions, transplant diagnostics, xeno products, and others. Organ preservation solutions are specially formulated liquids designed to maintain organ viability outside the body during transport and prior to transplantation. These products are applied in a variety of procedures, including kidney, heart, liver, and lung transplants, and are utilized by end users such as transplant centers, hospitals, and other healthcare facilities.

The cross-species organ transplantation market research report is one of a series of new reports that provides cross-species organ transplantation market statistics, including cross-species organ transplantation industry global market size, regional shares, competitors with a cross-species organ transplantation market share, detailed cross-species organ transplantation market segments, market trends and opportunities, and any further data you may need to thrive in the cross-species organ transplantation industry. The cross-species organ transplantation market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The cross-species organ transplantation market consists of revenues earned by entities by providing services such as preclinical and clinical xenotransplantation services, organ and tissue matching, post-transplant care and monitoring, and regenerative and bioengineered solutions. The market value includes the value of related goods sold by the service provider or included within the service offering. The cross-species organ transplantation market also includes sales of immunosuppressive drugs, bioengineered tissues, and organ scaffolds or matrices. Values in this market are ‘factory gate’ values; that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 3-5 business days.